Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHGE Stock Forecast 2026-2027
$0.21
Current Price
$2.48M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PHGE Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PHGE Price Momentum
-8.7%
1 Week Change
-61.8%
1 Month Change
-97.2%
1 Year Change
-88.8%
Year-to-Date Change
-98.5%
From 52W High of $13.70
+5.6%
From 52W Low of $0.20
📊 TOP ANALYST CALLS
Did PHGE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BiomX is one of their latest high-conviction picks.
Latest PHGE Stock Price Targets & Analyst Predictions
PHGE has shown a year-to-date change of -88.8% and a 1-year change of -97.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PHGE. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHGE Analyst Ratings
0
Buy
1
Hold
0
Sell
PHGE Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.21
Latest PHGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Nov 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 16, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 8, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 8, 2025 | HC Wainwright& Co. | Buy | Maintains | $N/A | |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 28, 2024 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| May 21, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 22, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 7, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 9, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 10, 2022 | Chardan Capital | Buy | Maintains | $N/A |
BiomX Inc. (PHGE) Competitors
The following stocks are similar to BiomX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BiomX Inc. (PHGE) Financial Data
BiomX Inc. has a market capitalization of $2.48M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -403.8%.
Valuation Metrics
Market Cap
$2.48M
Enterprise Value
$19.80M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+55.6%
Current Ratio
1.2x
Debt/Equity
0.0x
ROE
-403.8%
ROA
-62.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BiomX Inc. (PHGE) Business Model
About BiomX Inc.
What They Do
Develops microbiome-based therapeutics using bacteriophages.
Business Model
The company generates revenue by developing and commercializing microbiome-based therapeutics that target harmful bacteria using both natural and engineered phage cocktails. BiomX collaborates with pharmaceutical partners and healthcare providers to address chronic diseases linked to specific bacterial strains, leveraging its BOLT platform for discovery and validation of targeted therapies.
Additional Information
Founded in 2015 and headquartered in Ness Ziona, Israel, BiomX operates in a specialized niche within the health technology sector. Its focus on chronic conditions such as cystic fibrosis and diabetic foot osteomyelitis highlights its commitment to addressing significant unmet medical needs, creating potential for strong partnerships and growth in the biotechnology landscape.
Company Information
Sector
Industrials
Industry
Aerospace & Defense
Employees
20
CEO
Mr. Michael Oster
Country
United States
IPO Year
N/A
Website
www.biomx.comBiomX Inc. (PHGE) Latest News & Analysis
Latest News
Quick Summary
BiomX plans to acquire an Israeli company with 20 years of experience, enhancing its Detection-Analysis-Response strategy across various security and infrastructure technologies.
Why It Matters
The acquisition enhances BiomX's capabilities, potentially increasing market competitiveness and revenue, which could positively impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. announced that its subsidiary, Zorronet, has successfully transitioned its core operations to a new data center, enhancing its focus on defense and critical infrastructure technologies.
Why It Matters
The transition to a new data center indicates BiomX's commitment to enhancing operational efficiency and security, potentially leading to improved service delivery and revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. announced that its subsidiary Zorronet has started installing AI and ML systems for Israel Railways, aimed at wildlife protection and infrastructure safety, per a framework agreement.
Why It Matters
BiomX's involvement in AI and ML systems for Israel Railways indicates potential growth in technology adoption and infrastructure investment, which could enhance revenue and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. (PHGE) held a shareholder/analyst call, discussing company updates and financial performance. Further details on the call can provide insights for investors.
Why It Matters
The shareholder call indicates company performance, strategic direction, and financial health, influencing investor sentiment and stock price for BiomX Inc. (PHGE).
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. announced that its subsidiary DFSL will present new LADAR-based counter-drone and perimeter security solutions at ISC 2026.
Why It Matters
BiomX's showcase of innovative counter-drone technology could attract investment interest and partnerships, signaling potential growth and revenue opportunities in a high-demand security market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BiomX Inc. (NYSE American: PHGE) has completed its strategic transition to the defense sector and posted an updated presentation detailing its portfolio, leadership, and growth strategy on its website.
Why It Matters
BiomX's strategic shift to the defense sector signals potential growth and diversification, impacting its market position and investor sentiment in a high-demand industry.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHGE Stock
What is BiomX Inc.'s (PHGE) stock forecast for 2027?
Analyst forecasts for BiomX Inc. (PHGE) are not currently available. The stock is trading at $0.21.
Is PHGE stock a good investment in 2027?
According to current analyst ratings, PHGE has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHGE stock?
Price predictions from Wall Street analysts for PHGE are not currently available. The stock is trading at $0.21.
What is BiomX Inc.'s business model?
The company generates revenue by developing and commercializing microbiome-based therapeutics that target harmful bacteria using both natural and engineered phage cocktails. BiomX collaborates with pharmaceutical partners and healthcare providers to address chronic diseases linked to specific bacterial strains, leveraging its BOLT platform for discovery and validation of targeted therapies.
What is the highest forecasted price for PHGE BiomX Inc.?
Price targets from Wall Street analysts for PHGE are not currently available. The stock is trading at $0.21.
What is the lowest forecasted price for PHGE BiomX Inc.?
Price targets from Wall Street analysts for PHGE are not currently available. The stock is trading at $0.21.
What is the overall PHGE consensus from analysts for BiomX Inc.?
The overall analyst consensus for PHGE is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are PHGE stock price projections?
Stock price projections, including those for BiomX Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:04 AM UTC